Page 11234..1020..»

Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next … – P&T Community

Posted: February 23, 2017 at 6:49 pm

Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next …
P&T Community
23, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (CGI or The Company), a leader in precision diagnostics for oncology, announced today that Cancer Genetics India (CG India) and CSIR-Centre for Cellular and Molecular Biology …

More:
Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next … – P&T Community

Posted in Cancer Genetics | Comments Off on Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next … – P&T Community

Mean Rating Of Cancer Genetics, Inc. (NASDAQ:CGIX) At $1 – RealistInvestor.com

Posted: at 6:49 pm

On analysis of Cancer Genetics, Inc. (NASDAQ:CGIX) performance, 2 calls were listed. Its predicted price is $5.875.

Researchers have EPS forecast of $-0.22. Cancer Genetics, Inc. (NASDAQ:CGIX) will post quarterly report on 2017-03-09. It proclaimed EPS of $-0.23 for the quarter closed on 2016-09-30. Arithmetical mean was based on 2 ratings. A mean score of $1 was instituted.

Each quarter, listed firms submit their earnings to report overall performance. Using announced reports, stockholders know about the overall health of the entity, whether it is sales, costs, earnings or net income. Often, present and prospective investors measure an earnings report from earlier years.

There are various distinct ways to evaluate earnings report, but a better way to assess the actual posted statistics against what is anticipated by the street beforehand. Prior to fiscal earnings report announcement, analysts are questioned to know what report they are predicting. Mean is taken to get the forecast number. The street takes the forecasted number and discounts into the stock price.

Once financial report is publicized, the stock price impact comes into action. When the report is better than what was predicted, suppose the net profit is better than forecasters anticipation and other reported statistics in the fiscal report are enhanced than predicted, the stocks will instantly gain. If the fiscal report is revealed after-market hours, the opening price of the stock gains the following day. Most buyers and stockholders already are alert of this info.

Zacks scores are recognized in range of 1-5, where shareholders get the sentiment is optimistic when mark is 1. Sentiment turns adverse for shares with 5 score. Out of 2 analysts that researched Cancer Genetics, Inc., the best estimate is $6 for 2017. Lowest forecast during this period is $5.75. Researchers reported EPS prediction for Cancer Genetics, Inc. averaged at $-0.73.

EPS forecast range is $-0.74 to $-0.71. 1 researchers contributed EPS estimates and stated predicted growth rate at 40%.

This Little Known Stocks Could Turn Every $10,000 into $42,749!

Learn how you could trade stocks with 91% to 100% success rate by using this revolutionary indicator that predicts when certain stocks are on the move. You could be making up to 199% on a single trade in only 14 days.

Click Here to See This Now.

(Visited 5 times, 5 visits today)

Original post:
Mean Rating Of Cancer Genetics, Inc. (NASDAQ:CGIX) At $1 – RealistInvestor.com

Posted in Cancer Genetics | Comments Off on Mean Rating Of Cancer Genetics, Inc. (NASDAQ:CGIX) At $1 – RealistInvestor.com

New trial offers combination therapy to combat ovarian cancer – International Federation of Gynecology and Obstetrics

Posted: at 6:49 pm

A new clinical trial is offering combination therapy to directly kill ovarian cancer cells and teach the immune system to prevent them returning.

The clinical trial is focusing on women whose ovarian cancer results from mutated BRCA genes. It combines one drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.

Ovarian cancer does not have obvious symptoms and no screening tests that catch it in its early stages exist. This means that ovarian cancer frequently spreads to other organs before a woman even knows she has it.

Surgery and chemotherapy can help women at the beginning of their treatment, and this served as the inspiration for trial leader Dr Sarah Adams, of the University of New Mexico Comprehensive Cancer Center, US.

The study is focusing on women with BRCA1 and BRCA2 mutations. These are genetic mutations associated with a higher risk of breast and ovarian cancers.

More:
New trial offers combination therapy to combat ovarian cancer – International Federation of Gynecology and Obstetrics

Posted in Ovarian Cancer | Comments Off on New trial offers combination therapy to combat ovarian cancer – International Federation of Gynecology and Obstetrics

Study: Exercise reduces death rate from breast cancer – KOMO News

Posted: at 6:48 pm

Sometimes, simple things can be so powerful.

For example: Research shows that when a woman is diagnosed with breast cancer, exercise is the most important lifestyle factor that can help reduce her risk of death and prevent a recurrence of the disease. According to a new study published this week in the Canadian Medical Association Journal, physical activity can reduce breast cancer mortality by about 40%.

How much exercise?

Julia Hammer, who co-authored the study, recommends at least 150 minutes per week. And she told the Journal that it doesn’t seem to matter how much exercise you did before the diagnosis.

“So whether they were very active before or they’ve never worked out in their life, after a b reast cancer diagnosis there’s still a conferred benefit of exercising, she said.

Exercise helps fight depression, fatigue and stress. It also helps prevent swelling and weight gain, both common during treatment. The study found that a weight gain of more than 10 percent is linked to an increased risk of death.

More Info: Exercise a Powerful Ally for Breast Cancer Survivors

Read the rest here:
Study: Exercise reduces death rate from breast cancer – KOMO News

Posted in Breast Cancer | Comments Off on Study: Exercise reduces death rate from breast cancer – KOMO News

Molly Spillane’s fundraises for childhood cancer – Home Town Media Group

Posted: at 6:48 pm

Molly Spillanes is hoping to bring the Mamaroneck community together to brave the shave at its first annual St. Baldricks event.

For the past eight years, Stephen Carty, owner of Mickey Spillanes in Eastchester and Molly Spillanes in the village of Mamaroneck, has hosted a St. Baldricks head-shaving event at Mickey Spillanes to raise awareness for childhood cancer. Over this time, the bar has managed to raise more than $300,000.

With a new location scheduled this year, Carty is hoping for a high turnout and for Molly Spillanes to raise $15,000. As of press time, they have raised more than $4,000.

The event will be held at Molly Spillanes in Mamaroneck on Saturday, March 25.

The St. Baldricks Foundation, a nonprofit organization that aims to raise funds to help find cures for children with cancer, was started in 1999 by Tim Kenny, John Bender and Enda McDonnel, who came up with the idea to raise donations by promising to shave their heads. The idea behind the event is to show solidarity with children who have lost their hair from chemotherapy. Leading up to the event, participants raise money to be donated to the charity.

In 2016, there were 1,233 St. Baldricks events held worldwide and more than $38 million raised.

The St. Baldricks Foundation prides itself on being the largest private funder of childhood cancer research grants. Its website goes on to explain that 70 percent of the money raised every year goes toward research, 26 percent of funds goes toward fundraising for the events, and 4 percent goes toward the business side of the charity.

As charities go, its one that I felt was so upfront, no question where the money was going, Carty said.

Carty added that he intends to host St. Baldricks at Molly Spillanes for eight years, and then switch back to Mickey Spillanes for another eight.

The owner explained that Mickey Spillanes had a lot of involvement from police and fire departments.

Our first event [that] we had in Eastchester, it really was community driven, Carty said.

To date, the Eastchester EMS has gotten involved with Molly Spillanes and is currently ranked as the team with the top donations, having raised more than $2,000.

If we can just help one child with the funds raised here its great for everyone, Carty said.

Carty explained that one of the reasons the charity appeals to him is that St. Baldricks provides you with a list of cancer fighters and survivors in your area so that you can sponsor your own St. Baldricks event.

This year, Molly Spillanes is honoring 8-year-old Margaret Sheker from Larchmont. Sheker is a cancer survivor, having overcome acute lymphoblastic leukemia, which is a form of blood and bone marrow cancer.

Ashley Ferrara, co-organizer of the event and director of banquets at Molly Spillanes, said she is working on reaching out to another local child as well. This is Ferraras first year participating in fundraising for St. Baldricks and although she doesnt intend to shave her head, she has already raised $800 of her $2,000 goal.

The event has gotten everyone in the Molly Spillanes family involved.

Jake Terenzi, a part-time bartender at Molly Spillanes and co-organizer of the St. Baldricks event, said that getting on board with the event was an easy decision. He said that it sounded like a great idea, and wanted to help out as much as he could.

When he first got involved with the event he hadnt planned on shaving his head, but has since changed his mind. Its for the kids, I mean why not. Hair eventually grows back, he said.

Terenzi explained he has two goals for the event. One is to raise $2,000; he is currently at $525. His other goal is to get as many people to shave their heads as possible, which he explained has been harder than raising donations.

Last year, Mickey Spillanes was able to get 38 shavees; Molly Spillanes has a goal for this year of 40 people.

As of press time, Molly Spillanes has more than 10 people signed up to shave their heads, including Cartys wife, Geraldine Carty. My wife, five years ago, shaved off her hair, Carty said, adding that she raised roughly $20,000, and now shaves her head every year for the event.

Ferrara said that Trendon Lynch and Liam Quinn, both bartenders, are also planning to have their heads shaved.

And as the event day nears, Carty is hoping to get more of the local police and fire departments, and even the mayor, to participate.

Wed love everyone to get involved, [because cancer] has touched everyones life, Carty said.

comments

Read the original post:
Molly Spillane’s fundraises for childhood cancer – Home Town Media Group

Posted in Cancer Cures | Comments Off on Molly Spillane’s fundraises for childhood cancer – Home Town Media Group

Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care – Oncology Nurse Advisor

Posted: at 6:48 pm


Oncology Nurse Advisor
Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Oncology Nurse Advisor
Telehealth, the use of technology to exchange data and communicate between patients and health care providers, minimizes treatment burden, facilitates personal care, and provides reassurance to cancer survivors.1. With the survival rates of cancer …

Read more here:
Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care – Oncology Nurse Advisor

Posted in Oncology | Comments Off on Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care – Oncology Nurse Advisor

Eli Lilly & Co.’s Oncology Franchise – Market Realist

Posted: at 6:48 pm

Eli Lilly & Co.s Valuation after Its 4Q16 Earnings Release PART 6 OF 10

Eli Lilly and Co.s (LLY) Human Pharmaceuticals segment includes its Oncology franchise. Key drugs in this segment include Alimta, Erbitux, Cyramza, and Portrazza.

Alimta is a chemotherapy drug used in the treatment of patients with advanced non-small cell lung cancer. Alimtas sales fell~14% to $541.6 million during 4Q16, compared to $627.2 million for 4Q15. This included a 5% decrease in the US market and an ~21% decrease in international sales.

Alimta lost its market share to competition from other immuno-oncology products in the US markets. Its international sales were impacted by the continuous uptake of the generic version, as well as lower average prices. Alimta has a competitor drug from Allergan (AGN).

Erbitux is a drug used in the treatment of metastatic colorectal cancer, as well ashead and neck cancer. Erbituxs sales fell13% to $153.7 million in 4Q16, compared to ~$176.2 million in 4Q15. Eli Lilly took back the commercialization rights for Erbitux in North America from Bristol-Myers Squibb (BMY) on October 1, 2015.

Erbituxs US revenues fell due to initial stocking and competition from other immune-oncology drugs. Erbitux competes with Roches (RHHBY) Avastin and Amgens (AMGN) Vectibix.

LLYs Oncology franchise also includes Cyramza and Portrazza. Cyramzas revenues rose51% during 4Q16 following strong uptake in Japan and its launch in the European markets. Portrazza reported revenues of ~$4 million in 4Q16.

For broad-based industry exposure, investors can consider the PowerShares Dynamic Large Growth ETF (PWB) which invests 3.7% of its portfolio in Eli Lilly (LLY).

Here is the original post:
Eli Lilly & Co.’s Oncology Franchise – Market Realist

Posted in Oncology | Comments Off on Eli Lilly & Co.’s Oncology Franchise – Market Realist

AVEO Oncology (AVEO) Says TIVO-3 Passes The First Safety … – StreetInsider.com

Posted: at 6:48 pm

Get the Pulse of the Market with StreetInsider.com’s Pulse Picks. Get your Free Trial here.

AVEO Oncology (NASDAQ: AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by the studys Safety Monitoring Committee (SMC). The SMC concluded that no safety concern was observed for tivozanib and recommended that the study replace the small number of patients who dropped out prior to starting treatment.

As recently announced, the TIVO-3 trial is enrolling substantially ahead of schedule, and with the SMC recommendation to replace early dropouts the Company still expects to complete enrollment in June 2017, ahead of its prior guidance of August 2017. A pre-planned futility analysis of the trial is expected around midyear 2017, with topline data expected in the first quarter of 2018. The TIVO-3 trial, together with the previously completed TIVO-1 trial of tivozanib in the first line treatment of RCC, is designed to support regulatory approval of tivozanib in the U.S. as first and third line treatment for RCC.

Tivozanib is a unique molecule in that its high selectivity for VEGF is designed to reduce off target toxicity, thereby increasing tolerability and its combinability with other agents, such as immunotherapies, said Michael Needle, M.D., chief medical officer of AVEO. We are very pleased to see the pace at which TIVO-3 is enrolling, and that it has completed its first safety review. We look forward to the futility analysis around midyear, and to other potential achievements in our tivozanib clinical program, including the expected first patient treated in the tivozanib and Opdivo combination study, TiNivo, in early March.

Original post:
AVEO Oncology (AVEO) Says TIVO-3 Passes The First Safety … – StreetInsider.com

Posted in Oncology | Comments Off on AVEO Oncology (AVEO) Says TIVO-3 Passes The First Safety … – StreetInsider.com

Cyclacel’s stock plunges after disappointing trial results of its cancer treatment – MarketWatch

Posted: at 6:46 pm

Cyclacel's stock plunges after disappointing trial results of its cancer treatment
MarketWatch
Shares of Cyclacel Pharmaceuticals Inc. CYCC, -20.70% plunged 19% in premarket trade Thursday, after disappointing late-stage trial results of its leukemia treatment. The company said a phase 3 Seamless trial of its treatment of newly diagnosed acute …

and more »

Link:
Cyclacel’s stock plunges after disappointing trial results of its cancer treatment – MarketWatch

Posted in Cancer Treatment | Comments Off on Cyclacel’s stock plunges after disappointing trial results of its cancer treatment – MarketWatch

Incyte pens cancer IO pact with University of Pennsylvania’s cancer center – FierceBiotech

Posted: at 6:46 pm

Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. Since then the biotech has been looking to I-O combos, and today it has broadened its reach with a new cancer immunotherapy deal with the University of Pennsylvania.

Exact financial details and length of the collaboration have not been revealed, but the company said it has inked a multi-year deal with the Abramson Cancer Center, based out of the University of Pennsylvania.

Within the deal, Penn scientists will work with Incyte on their drug development efforts and help the company better understand their mechanisms of action that, Incyte says, will further develops the clinical rationales for combination therapy and patient selection. The pair will also team up to develop a bioinformatics program in clinical immunotherapy.

Incyte will provide undisclosed sums for these research programs, and could also work on extra grant-funded research with Penn investigators in other areas of cancer immunology.

Incyte and Abramson are mutually committed to the advancement of science and improving the lives of patients with cancer. This alliance will allow us to mobilize two groups of leading scientists toward the collective goal of advancing the field of immunotherapy, said Reid Huber, CSO at Incyte.

We are excited for the opportunity to partner with the world-class researchers at Abramson and investigate new avenues for the treatment of patients with cancer.

Penn researchers are also working on the early stages of the gene editing tech CRISPR, as well as on the cousin tech CAR-T at the Novartis-Penn Center for Advanced Cellular Therapeutics.

A year ago, Incyte stopped a range of studies for myelofibrosis med Jakafi (ruxolitinib) as well as the experimental INCB39110, another JAK1. Already halted on one colon cancer trial failure, Incyte also ended the phase 3 pancreatic cancer study, a separate midstage trial in colorectal cancer, a phase 2 for breast and lung cancers and a dose-ranging trial for INCB39110 in pancreatic cancer.

But since then it has been ramping up its efforts in I-O, with a late-stage combo trial announced in the summer with Merck that sees Incytes experimental oral IDO1 inhibitor epacadostat used alongside the Big Pharmas marketed PD-1 Keytruda (pembrolizumab), as a first-line treatment for patients with advanced or metastatic melanoma.

It also published a broadly positive trial update from its small, phase 1 melanoma trial in October with Keytruda and epacadostat, and last month paid $53 million upfront for Calithera Biosciences small molecule arginase inhibitor CB-1158, which the biotechs see as complementing PD-1 drugs by reversing an immunosuppressive block that dampens the activity of immuno-oncology therapies.

Go here to see the original:
Incyte pens cancer IO pact with University of Pennsylvania’s cancer center – FierceBiotech

Posted in Cancer | Comments Off on Incyte pens cancer IO pact with University of Pennsylvania’s cancer center – FierceBiotech

Page 11234..1020..»